News
Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results